SBIR/STTR Research Award

Preparation and submission of an IND for PPCM Gel contraceptive

Award identifier d0bc61abadf500ea2a7efc6baf3bac7500eb7a7032d3e907aa773ece67a6e11aAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$298,521

Program and phase

SBIR · Phase I

Award year

2022

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
YASO THERAPEUTICS CORPORATION
Proposal award date
2022-04-06
Contract end date
2022-10-01
UEI
GHMJR4AX38G9
Solicitation number
PA21-259
Topic code
NICHD

Research abstract

PROJECT SUMMARY Polyphenylene carboxymethylene sodium salt (PPCM) is being developed by Yaso Therapeutics as a woman-controlled, on-demand vaginal contraceptive gel (PPCM-GEL) with a unique, non-cytotoxic mechanism that triggers premature acrosomal loss of sperm, rendering them incapable of fertilization. Since PPCM also binds highly conserved glycosaminoglycans, this novel gel has additional potential to function as a multipurpose prevention technology (MPT) that protects against important bacterial and viral sexually transmitted infections (STIs). Under this grant we propose to complete one last packaging compatibility and stability study of PPCM-GEL, complete writing the IND per eCTD and FDA guidelines, and have a regulatory consulting firm electronically submit the IND to FDA. With the support of prior NIAID and NICHD grants (R42AI069659, R43/44AI084225,5R44HD092206), we have advanced PPCM through preclinical evaluation and have successfully formulated a mucoadhesive, non- irritating vaginal gel that is ready for clinical evaluation. The mechanism of action on sperm has enabled us to conduct pre-clinical studies using a commercially available sperm quality biomarker, hyaluronan binding assay (HBA®) to assess potential contraceptive activity. In pre-clinical testing, we have also demonstrated potent activity against Neisseria gonorrhoeae, herpes simplex virus, and HIV. PPCM-GEL is formulated for non- systemic topical use, is non-hormonal, and has potential to be one of the first successful MPT products with contraceptive and broad STI/HIV prevention efficacies. The prevalence of unplanned pregnancy and STIs among women in all economic, social, and cultural circumstances has remained high despite existing prevention options. There is a long-standing paucity of available on-demand and nonhormonal broad-spectrum prevention options. Availability of a dual-purpose product for contraception and STI/HIV prevention will arm people with an important option for reproductive health.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

7 SBIR/STTR records share this UEI (2006–2025). Reported award amounts total $7,233,642. Reported amounts are not federal obligations.

Phases: Phase II, Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.